December 2, 2011 — Lysosomal storage disorders such as Fabry's disease and Pompe's disease are much more common than previously thought, particularly atypical later-onset forms, a new study suggests.

The Global Lysosomal Storage Disorders (LSDs) Market is expected to reach at a CAGR of 6.6% during the forecast period 2025-2033. The Global Lysosomal Storage Disorders (LSDs) Market is rapidly ...

The Lysosomal Storage Disease Treatment Market is expanding due to increased diagnosis rates and innovations in enzyme ...

An analysis of dried blood spots from around 35 000 babies in Austria has shown that lysosomal storage disorders—those in which the lysosome or 'recycling centre' of the body's cells malfunctions—are ...

This new analysis shows early diagnosis of some lysosomal storage disorders can help avoid irreversible damage across the board. Lysosomal storage disorders (LSDs), including Gaucher disease (GD), ...

Please provide your email address to receive an email when new articles are posted on . An Italian pharmaceutical company and a Boston-area biotechnology research firm announced a partnership to ...

A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.

ST. LOUIS--(BUSINESS WIRE)--M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced ...

ST. LOUIS--(BUSINESS WIRE)--M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage ...

Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, filed on Friday with the SEC to raise up to $40 million in an initial public offering.

According to DataM Intelligence, Metabolic Disorders Therapeutics Market Size was valued at US$74.97 billion in 2024 and is ...

Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, announced terms for its IPO on Wednesday. The Bethesda, MD-based company plans to raise ...